Carcinogenesis, Vol 18, 2009-2014, Copyright © 1997 by Oxford University Press
BA Diwan, LM Anderson and JM Ward
Tamoxifen (TAM) is widely used as adjuvant breast cancer therapy after
surgery and as a chemopreventive agent in women of child-bearing age.
However, TAM therapy has been shown to result in an increased incidence of
endometrial carcinoma in women. The present study was designed to
investigate the effects of TAM (5 mg/kg and 7.5 mg/kg body wt) given i.g.
to pregnant CD-1 mice (1x/day, days 12 through 18 of gestation) on their
female offspring. Progressive proliferative hyperplasia of the oviduct was
frequently seen in TAM-exposed offspring, reaching 100% incidence by 52
weeks in both treatment groups. These females also developed progressive
proliferative uterine lesions, including moderate/severe cystic endometrial
hyperplasia (34-50%) and polypoid adenomas (27-30%) between 53 and 78
weeks. Deciduomas (15%) occurred at young ages (12 and 24 weeks) while
leiomyomas (14%), a malignant leiomyosarcoma, and ovarian granulosa cell
tumors (14%), were found between 72 and 78 weeks. Our findings thus suggest
a strong association between transplacental TAM and reproductive tract
abnormalities in female CD-1 mice.
ARTICLES
Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen
Intramural Research Support Program, SAIC Frederick, National Cancer Institute, Frederick Cancer Research and Development Center, MD 21702- 1201, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. P. Waalkes, J. Liu, J. M. Ward, D. A. Powell, and B. A. Diwan Urogenital Carcinogenesis in Female CD1 Mice Induced by In utero Arsenic Exposure Is Exacerbated by Postnatal Diethylstilbestrol Treatment Cancer Res., February 1, 2006; 66(3): 1337 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jakacka, M. Ito, F. Martinson, T. Ishikawa, E. J. Lee, and J. L. Jameson An Estrogen Receptor (ER){alpha} Deoxyribonucleic Acid-Binding Domain Knock-In Mutation Provides Evidence for Nonclassical ER Pathway Signaling in Vivo Mol. Endocrinol., October 1, 2002; 16(10): 2188 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Miller, M. A. Marty, A. Arcus, J. Brown, D. Morry, and M. Sandy Differences Between Children and Adults: Implications for Risk Assessment at California EPA International Journal of Toxicology, September 1, 2002; 21(5): 403 - 418. [Abstract] [PDF]
|
|
|
|
 |
|
 R. L. Divi, Y. P. Dragan, H. C. Pitot, and M. C. Poirier Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen Carcinogenesis, October 1, 2001; 22(10): 1693 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hilakivi-Clarke, E. Cho, I. Onojafe, D. J. Liao, and R. Clarke Maternal Exposure to Tamoxifen during Pregnancy Increases Carcinogen-induced Mammary Tumorigenesis among Female Rat Offspring Clin. Cancer Res., January 1, 2000; 6(1): 305 - 308. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Divi, M. R. Osborne, A. Hewer, D. H. Phillips, and M. C. Poirier Tamoxifen-DNA Adduct Formation in Rat Liver Determined by Immunoassay and 32P-Postlabeling Cancer Res., October 1, 1999; 59(19): 4829 - 4833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Sohal, M. Nghiem, M. A. Crackower, S. A. Witt, T. R. Kimball, K. M. Tymitz, J. M. Penninger, and J. D. Molkentin Temporally Regulated and Tissue-Specific Gene Manipulations in the Adult and Embryonic Heart Using a Tamoxifen-Inducible Cre Protein Circ. Res., July 6, 2001; 89(1): 20 - 25. [Abstract] [Full Text] [PDF]
|
|